Vnitr Lek 2022, 68(2):124-126 | DOI: 10.36290/vnl.2022.023

Any expectations from the more powerful dulaglutide?

Jan Škrha jr.
3. interní klinika 1. LF UK a VFN, Praha

Dulaglutide is a frequently used GLP-1 analogue and one of the most potent antidiabetic drugs. Practical aspects of treatment with dulaglutide are presented in this article, together with new data from AWARD-11 study with higher concentrations of dulaglutide, especially the effects on diabetes control, body weight and side effects.

Keywords: dulaglutide, pharmacotherapy, diabetes.

Published: April 4, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Škrha J. Any expectations from the more powerful dulaglutide? Vnitr Lek. 2022;68(2):124-126. doi: 10.36290/vnl.2022.023.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Haluzík M. Dulaglutid. Farmakoterapie. 2018;14(1):59-64.
    2. Adamíková A. Dulaglutid. Interní Medicína. 2019;21(1):62-65. Go to original source...
    3. Mody R, Huang Q, Yu M et al. Clinical and economic outcomes among injection‑naive patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real‑world setting: the DISPEL Study. Bmj Open Diabetes Research & Care 2019;7(1). Go to original source... Go to PubMed...
    4. Gerstein HC, Colhoun HM, Dagenais GR et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double‑blind, randomised placebo‑controlled trial. Lancet 2019;394(10193):121-130. Go to original source... Go to PubMed...
    5. Buse JB, Wexler DJ, Tsapas A et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020;43(2):487-493. Go to original source... Go to PubMed...
    6. Gerstein HC, Colhoun HM, Dagenais GR et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo‑controlled trial. Lancet 2019;394(10193):131-138. Go to original source... Go to PubMed...
    7. Committee ADAPP. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care 2021;45(Supplement_1):S144-S174. Go to original source... Go to PubMed...
    8. Frias JP, Bonora E, Nevarez Ruiz L et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin‑Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care 2021;44(3):765-773. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.